Klin Farmakol Farm. 2015;29(2):62-64
Treatment of the most common herpetic infections and options for herpes zoster prevention
- Dermatovenerologie, Nemocnice Na Homolce, Praha
- L DermaMedEst, s. r. o., Praha
Herpetic infections are caused by herpesviruses and are among very frequent skin conditions. The diseases are caused by DNA viruses that are antigenically homogeneous. Man is the only virus source and host. Seroprevalence of the population is very high, up to 90%. Herpes simplex and varicella are the most common skin conditions. Viruses causing these diseases persist in the ganglia of the nervous system and when the body's defence system is reduced, their reactivation occurs. The herpes simplex virus (HSV) causes herpes labialis (with HSV1 being the most common causative agent) and genital herpes (with HSV2 being the most common causative agent). The varicella- zoster virus (VZV) causes two distinct conditions: chickenpox(varicella) and shingles (herpes zoster). Since April 2014, a vaccine against herpes zoster has been available in the Czech Republic as the first among central and eastern European countries.
Keywords: DNA viruses, herpesvirus, varicella-zoster virus, varicella, herpes zoster, postherpetic neuralgia, pain, antiviral drugs, prevention
Published: July 1, 2015 Show citation
References
- Havlík J. Infekční nemoci - příručka pro praktické lékaře, Galen, Praha, 1998: 221.
- Gross M. Příručka léčebné lokální anestezie, Grada, Praha 1997: 214.
- Albe - Fessard D. Bolest - mechanizmy a základy léčení, Grada, Praha 1998: 224.
- Ambler Z, Bednařík J, Keller O. Doporučený postup pro léčbu neuropatické bolesti, Čes. A Slov. Neurol. Neurochir., 2002; 65/98: 135-138.
- Opavský R. Postherpetická neuralgie a její léčba, Dermatol. praxi, Solen, 2009; 3(1): 74-75.
- Hales CM, Harpaz R, Joesoef MR, Bialek SR. Examination of links between herpes zoster incidence and childhood varicella vaccination. Ann Intern Med 2013; 159: 739-745.
Go to original source... 
Go to PubMed... - Ortega-Sanchez IR. Decision and cost-effectiveness analyses of herpes zoster vaccination in adults 50 years of age and older. [Presentation] Atlanta, GA: US Department of Health and Human Services, CDC; 2013.
- Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007; 82: 1341-1349. Go to original source... Go to PubMed...
- Bednařík J, Ambler Z, Opavský J, et al. Standard pro farmakoterapii neuropatické bolesti. http://www.czech-neuro.cz/att/s/o/9/phpso9CRP.pdf nebo http://www.nrc.cz/files/NPBOL_VO-0-03.
- Gilden DH, Kleinschmidt-DeMasters BK, LaGuardia JJ, Mahalingam R, Cohrs RJ. Neurologic complications of the reactivation of varicella-zoster virus [published correction appears in N Engl J Med. 2000; 342(14): 1063] N Engl J Med. 2000; 342(9): 635-645. Go to original source... Go to PubMed...